Clinical Efficacy and Impact on Lung Function of Nicotinic Acid Com-bined with Methylprednisolone Sodium Succinate in the Treatment of COPD Patients with Respiratory Failure
Objective To investigate the role of nicoxamide and methylprednisolone succinate in the treatment of re-spiratory failure in chronic obstructive pulmonary disease(COPD).Methods 464 COPD patients with respiratory fail-ure admitted to the Respiratory and Critical Care Medicine of Yancheng First People's Hospital from January 2021 to May 2023 were randomly selected as the study objects,and were divided into control group and study group according to different treatment methods,with 232 cases in each group.The control group received nikosamine injection,and the study group combined methylprednisolone sodium succinate based on the control group.After 7 days of treatment,the clinical efficacy,lung function and incidence of adverse reactions were compared between the two groups.Results The effective rate of the study group was 93.10%(216/232),which was higher than 87.50%(203/232)of the control group,the difference was statistically significant(χ2=4.159,P<0.05).The level of lung function indexes in the study group were better those in the control group,the differences were statistically significant(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The com-bined use of nicotinic acid and methylprednisolone sodium succinate has a significant therapeutic effect on COPD pa-tients with respiratory failure.It can improve clinical efficacy,improve lung function levels,and does not increase ad-vrse rectins.
NETL
NSTL
万方数据
